- Roivant Sciences press release ( NASDAQ: ROIV ): Q3 GAAP EPS of -$0.49 misses by $0.09 .
- Revenue of $17.05M (-30.0% Y/Y) beats by $2.27M .
- $9.2M in net product revenue from VTAMA reported for the quarter ended December 31, 2022, with nearly 100,000 VTAMA prescriptions written by approximately 8,600 unique prescribers since launch
- As of December 31, 2022, the company had cash, cash equivalents and restricted cash of approximately $1.5 billion.
- Shares -0.88% PM.
For further details see:
Roivant Sciences GAAP EPS of -$0.49 misses by $0.09, revenue of $17.05M beats by $2.27M